Ambrotose AO® capsules granted Decision to
Grant for Europe and patent in Indonesia
COPPELL, Texas--(BUSINESS WIRE)--Feb. 26, 2014--
Incorporated (NASDAQ: MTEX), the founder of the M5MSM
(Mission 5 MillionSM) social entrepreneurial movement,
the pioneer of nutritional glycobiology and the leading innovator of
naturally-sourced supplements based on Real
Food Technology® solutions, announces the issuance of two
new patents pertaining to its Ambrotose
AO formulations, increasing the total patents held by the company to
more than 90.
“While the vast majority of antioxidant supplements rely on high-dose
synthetic ingredients,” said Dr. Sinnott, CEO and Chief Science Officer
at Mannatech, “we knew back in 2003 when we launched Ambrotose AO that a
better approach would be to formulate a synergistic blend of fat- and
water-soluble food-sourced antioxidant nutrients that resemble the
nutrients found in a diet rich in fresh fruits and vegetables. Proof of
the benefit of Ambrotose AO supplementation, as measured by increased
serum oxygen radical antioxidant capacity (ORAC), has been confirmed in
three human clinical trials.1,2,3 The product’s safety has
been confirmed during these studies and by 11 years of data collected by
our outstanding Safety Monitoring Program.”*
Mannatech received the Decision to Grant from the European Patent Office
and was issued the Letters Patent for Indonesia pertaining to its
Ambrotose AO formulation. More than 25 patents have been issued
worldwide to Mannatech for the technology pertaining to this
formula. Overall, more than 90 patents have been issued worldwide to
Mannatech for the technology pertaining to its Ambrotose, Ambrotose AO,
GI-ProBalance®, and PhytoMatrix® product
formulations and in the field of biomarker assays.
“Mannatech had the foresight to begin developing its patent portfolio in
the mid-1990s,” continued Dr. Sinnott. “These two new patents are a
direct result of our systematic research and intellectual property
development which has continued without pause since the company began.”
Individuals interested in Mannatech’s products, or exploring its social
entrepreneurial efforts to help fight global malnutrition, can learn
more at Mannatech.com.
Those interested in obtaining technical information and reading
published product studies may visit MannatechScience.org.
Mannatech, Incorporated, develops high-quality health, weight and
fitness, and skin care products that are based on the solid foundation
of nutritional science and development standards. Mannatech is dedicated
to its platform of Social Entrepreneurship based on the foundation of
promoting, aiding and optimizing nutrition where it is needed most
around the world. Mannatech’s proprietary products are available through
independent sales Associates around the globe, including the United
States, Canada, South Africa, Australia, New Zealand, Austria, Denmark,
Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan,
Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech
Republic, the Republic of Korea, Mexico, Namibia, Hong Kong and Ukraine.
For more information, visit Mannatech.com.
Please note: This release contains “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as amended,
and the Private Securities Litigation Reform Act of 1995. These
forward-looking statements generally can be identified by use of phrases
or terminology such as “intend” or other similar words or the negative
of such terminology. Similarly, descriptions of Mannatech’s objectives,
strategies, plans, goals or targets contained herein are also considered
forward-looking statements. Mannatech believes this release should be
read in conjunction with all of its filings with the United States
Securities and Exchange Commission and cautions its readers that these
forward-looking statements are subject to certain events, risks,
uncertainties and other factors. Some of these factors include, among
others, Mannatech’s inability to attract and retain Associates and
Members, increases in competition, litigation, regulatory changes and
its planned growth into new international markets. Although Mannatech
believes that the expectations, statements and assumptions reflected in
these forward-looking statements are reasonable, it cautions readers to
always consider all of the risk factors and any other cautionary
statements carefully in evaluating each forward-looking statement in
this release, as well as those set forth in its latest Annual Report on
Form 10-K and Quarterly Report on Form 10-Q, and other filings filed
with the United States Securities and Exchange Commission, including its
current reports on Form 8-K. All of the forward-looking statements
contained herein speak only as of the date of this release.
1. Boyd S, Gary K, Koepke CM, et al. An open-label pilot study of the
antioxidant effect in healthy people of Ambrotose AO. GlycoScience &
Nutrition 2003; 4(6): 1-6.
2. Myers SP, Stevenson L, Cheras PA, et al. A forced titration study of
the antioxidant and immunomodulatory effects of Ambrotose AO supplement. BMC
Comp Alt Med 2010; 10(16): 1-16.
3. Bloomer RJ, Canale RE, Blankenship MM, et al. Effect of Ambrotose AO
on resting and exercise-induced antioxidant capacity and oxidative
stress in healthy adults. Nutr J 2010; 9(49): 1-17.
These studies were funded by Mannatech.
*These statements have not been evaluated by the U.S. Food and Drug
Administration. These products are not intended to diagnose, treat, cure
or prevent any disease.
Source: Mannatech, Incorporated
Brett Duncan, 972-471-7367